Thechemical class of PPARγ agonists known as thiazolidinediones (TZDs)demonstrated high-affinity binding to PPARγ [7] as well as favorable therapeuticproperties, and such drugs were eventually registered for the treatment of typeII diabetes mellitus (T2DM). Here, PPARG is linked to type 2 diabetes mellitus.